

Prevalence of Methicillin-Resistant Staphylococci in Dogs ^[1]

Özkan ASLANTAŞ *  Süheyla TÜRKYILMAZ ** Mehmet Ali YILMAZ ***
Ebru Şebnem YILMAZ ****

[1] This study was funded by Mustafa Kemal University Scientific Research Project Fund (BAP-1001 M 0104)

* Mustafa Kemal University, Faculty of Veterinary Medicine, Department of Microbiology, TR-31034 Hatay - TURKEY

** Adnan Menderes University, Faculty of Veterinary Medicine, Department of Microbiology, TR-09010 Aydın - TURKEY

*** Susuz District Agricultural Directorate, TR-36760 Susuz, Kars - TURKEY

**** Mustafa Kemal University, Faculty of Art and Science, Department of Biology, TR-31034 Hatay - TURKEY

Makale Kodu (Article Code): KVFD-2012-7073

Summary

The aim of the study was to investigate the occurrence and species distribution of methicillin resistant staphylococci (MRS) in the nasal cavity of dogs. Nasal swabs were collected from 162 dogs entering private veterinary clinics in Hatay. Methicillin resistance was detected onto mannitol salt agar containing 2 µg/ml oxacillin and confirmed by *mecA* Polymerase Chain Reaction (PCR). Bacterial identification was done using 16S rRNA sequencing. Staphylococcal cassette chromosome *mec* (SCC*mec*) typing of these isolates were determined by multiplex PCR. Antimicrobial susceptibility testing were performed disk diffusion method and antimicrobial resistance genes were determined by PCR. Methicillin-resistant coagulase negative staphylococci (MRCNS) harbouring *mecA* were isolated from 15.4% (25/162) of dogs. The species identified were *S. epidermidis* (n=12), *S. lentus* (n=6), *S. hominis* (n=4), *S. warneri* (n=1), *S. arlettae* (n=1) and *S. haemolyticus* (n=1). *mecA*-mediated methicillin resistance in *S. arlettae* was described for the first time. Methicillin resistant *Staphylococcus aureus* (MRSA) and methicillin resistant *Staphylococcus pseudintermedius* (MRSP) were not detected. SCC*mec* type I, II, III and IV were identified in 1, 10, 9 and 5 MRS isolates, respectively. The results indicate that continuous surveillance is necessary to determine the emergence of MRS including MRSA.

Keywords: Dog, Methicillin resistance, Staphylococci

Köpeklerde Metisilin Dirençli Stafilokokların Prevalansı

Özet

Bu çalışmanın amacı, köpeklerin nazal mukozalarında metisilin dirençli stafilokokların (MRS) varlığının ve tür dağılımının belirlenmesidir. Bu amaçla, Hatay'da özel veteriner kliniklerine getirilen 162 köpekten nazal svablar alındı. Metisilin direncinin belirlenmesinde 2 µg/ml oksasillin içeren mannitollü tuzlu agar kullanıldı. Bakteriyel identifikasyon 16S rRNA dizi analizi ile gerçekleştirildi. Stafilokokal kromozomal kaset tiplendirmesi (SCC*mec*) için multipleks polimeraz zincir reaksiyonu (mPZR) yapıldı. Antimikrobiyal duyarlılıkları disk difüzyon yöntemi ile ve antimikrobiyal direnç genleri PZR ile incelendi. Köpeklerin %15.42'ünden (25/162) *mecA* geni taşıyan MRS izole edildi. Yirmibeş MRS izolatu *S. epidermidis* (n=12), *S. lentus* (n=6), *S. hominis* (n=4), *S. warneri* (n=1), *S. arlettae* (n=1) ve *S. haemolyticus* (n=1) olarak tanımlandı. *S. arlettae*'de *mecA* geni ilk kez belirlendi. Metisilin dirençli *S. aureus* (MRSA) ve *S. pseudintermedius* (MRSP) izole edilmedi. SCC*mec* tip I, II, III ve IV sırasıyla 1, 10, 9 and 5 MRS izolatında belirlendi. Sonuçlar, MRSA dahil MRS suşlarının ortaya çıkışını belirlemek için sürekli surveyansın gerekli olduğunu işaret etmektedir.

Anahtar sözcükler: Köpek, Metisilin Direnci, Stafilokok

INTRODUCTION

Emergence of methicillin resistant staphylococci (MRS), particularly methicillin resistant *Staphylococcus aureus* (MRSA) and *Staphylococcus pseudintermedius* (MRSP) in pet animals, is public and animal health concern due to

zoonotic transmission of these multidrug resistant bacteria. MRSA strains found in dogs in various countries have been shown to be same clones isolated from humans in the region ¹. However, methicillin resistance among coagulase



İletişim (Correspondence)



+90 326 2455845/1523



ozkanaslantas@yahoo.com, aslantas@mku.edu.tr

negative staphylococci (CNS) have been reported with increased frequency in human and veterinary medicine²⁻⁶. As there is limited data on the presence of MRSA, MRSP and other MRS in dog population in Turkey. This study investigated the prevalence of MRS carriage among dogs presenting private veterinary clinics in Hatay, Turkey.

MATERIAL and METHODS

Sample Collection

From December 2008 to June 2009, nasal swabs were obtained from 162 dog attending private veterinary clinics in Hatay, Turkey. This study was approved by the Animal Ethical Committee of Mustafa Kemal University (2008/78).

Sample Analysis

The swabs were placed in enrichment broth containing 10 g/l mannitol, 65 g/l sodium chloride, 2.5 g/l yeast extract and 10 g/l tryptone containing 2 µg/ml oxacillin and incubated at 35°C for 24 h. Subsequently, 10 µl inoculum was spread onto Mannitol Salt Agar containing 2 µg/ml oxacillin as above and incubated 35°C for 24-48 h. A single presumptive methicillin resistant staphylococcal colony was selected and identified phenotypically on the genus level by conventional biochemical tests.

DNA Extraction

Genomic DNA from individual pure cultures of MRCNS isolates were extracted with InstaGene matrix (Bio-Rad Laboratories, Canada) according to the manufacturer's instructions.

Identification and Characterisation of MRS Isolates

For the detection of *mecA* (methicillin resistance) gene, the oligonucleotide primers and PCR conditions used for this study were performed as reported previously by Oliveira and de Lencastre⁷. 16S rRNA gene amplification and sequence analysis were performed as described previously^{8,9}. Thus, a large, 1371 bp fragment encoding 16S rRNA gene was amplified and subjected to sequence analysis for species discrimination. For the detection of 16S20 and 16S1390 universal rRNA, primers 5'-AGA GTT TGA TCC TGG CTC AG -3' and 5'-GAC GGG CGG TGT GTA CAA -3' were used as the forward and the reverse primer, respectively^{10,11}. Nucleotide sequences were compared with the published sequences on National Center of Biotechnology Information (available online at <http://www.ncbi.nlm.nih.gov>), and sequences showing highest similarity score (>97%) to a type strain was considered as species identity.

SCCmec Typing

SCCmec types (I-IV) of the isolates were determined using methods and primers described by Oliveira and de Lencastre⁷. For the detection of *mecA* (methicillin

resistance) gene and SCCmec typing, methicillin susceptible (*Staphylococcus aureus* ATCC 29213) and methicillin resistant (*S. aureus* HPV107, *S. aureus* BK2464, *S. aureus* HUSA304, *S. aureus* GRE14) reference strains used as negative and positive control in PCR, respectively. Visualization of PCR products was performed on 1.5% agarose gel stained with ethidium bromide.

Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing of MRS strains was performed according to the guideline of Clinical and Laboratory Standards Institute (CLSI)¹² using the following antimicrobial disks: erythromycin (15 µg), trimethoprim-sulfamethoxazole (1.25 µg/23.75 µg), vancomycin (30 µg), gentamicin (10 µg), quinopristin-dalfopristin (15 µg), ciprofloxacin (5 µg), mupirocin (5 µg), fusidic acid (10 µg), rifampicin (5 µg), amoxicillin-clavulanic acid (20 µg/10 µg), clindamycin (2 µg) and tetracycline (30 µg). Since standardized CLSI breakpoint for mupirocin and fusidic acid are not available, the disk diffusion testing of these antibiotics was performed as previously reported^{13,14}.

Determination of Antimicrobial Resistance Genes

PCR assays for the resistance genes *ermA*, *ermB*, *ermC*, *msrA*, *mphC*, *lunA*, *aac(6')/aph(2'')*, *aph(3')-IIIa*, *ant(4)-Ia*, *tetK*, *tetM*, *ileS-2*, *fusB*, *fusC* was performed as previously reported¹⁵⁻²¹.

RESULTS

Identification, Characterisation and SCCmec Types of MRS Isolates

MRS was isolated from 25 dogs (15.4%). Identification of isolates was done by sequencing a 1371 bp size PCR product by using universal 16S rRNA primers (Fig. 1). 16S rRNA sequencing of isolates revealed the occurrence of seven species: *S. epidermidis* (n=12), *S. lentus* (n=6), *S. hominis* (n=4), *S. warneri* (n=1), *S. arlettae* (n=1) and *S. haemolyticus* (n=1) (Table 1). No dogs were colonized with MRSA and MRSP. The most prevalent SCCmec type were SCCmec II (40%), followed by SCCmec III (36%), SCCmec IV (20%), and SCCmec I (4%) (Fig. 2, 3). While 20 isolates including type I, II and III were defined as hospital acquired methicillin resistant staphylococci (HA-MRS), 5 isolates including type IV were community acquired methicillin resistant staphylococci (CA-MRS).

Antimicrobial Susceptibility Testing

Ninety-two percent of isolates displayed resistance to at least one antimicrobial agent. Many MRCNS isolates were frequently resistant to erythromycin (14/25, 56%), tetracycline (13/25, 52%) and clindamycin (8/25, 32%). In addition, six (24%) of the isolates were resistant to ciprofloxacin and trimethoprim-sulfamethoxazole, five (20%) to gentamicin




Fig 1. PCR performed by using 16S rRNA universal primers. M: Marker (Lambda phage DNA restricted with *Pst*I enzyme) 1-6: PCR performed by using isolated microorganism's DNA. PK: Positive control (*S. aureus* HPV107), NK: Negative control (master mix without DNA)

Şekil 1. 16S universal primerleri kullanılarak gerçekleştirilen PZR. M: Marker (*Pst*I enzimi ile kesilmiş lambda faj DNA'sı). PZR. 1-6: *Staphylococcus* izolatları, PK: Pozitif kontrol (*S. aureus* HPV107), NK: Negatif kontrol (DNA'sız master miks)

Fig 2. SCCmec types determined in MRS isolates. Lane M: 100 bp molecular marker. Lane 1-13: SCCmec types belong to different MRS isolates, Lane NC: Negative control (master mix without DNA), Lane I: *S. aureus* HPV107 (SCCmec type I), Lane II: *S. aureus* BK2464 (SCCmec type II), Lane III: *S. aureus* HUSA304 (SCCmec type III), Lane IV: *S. aureus* GRE14 (SCCmec type IV)

Şekil 2. MRS izolatlarında belirlenen SCCmec tipleri. M: 100 bp moleküler marker, 1-13: Farklı MRS izolatlarına ait SCCmec tipleri. NK: Negatif kontrol, I: *S. aureus* HPV107 (SCCmec tip I), II: *S. aureus* BK2464 (SCCmec tip II), III: *S. aureus* HUSA304 (SCCmec tip III), IV: *S. aureus* GRE14 (SCCmec tip IV)




Fig 3. SCCmec types determined in MRS isolates. Lane M: 100 bp molecular marker. Lane 14-25: SCCmec types belong to different MRS isolates

Şekil 3. MRS izolatlarında belirlenen SCCmec tipleri. M: 100 bp moleküler marker. 14-15: Farklı MRS izolatlarına ait SCCmec tipleri

and mupirocin, three (12%) to rifampicin and one (4%) to quinopristin-dalfopristin, fusidic acid, and amoxicillin-clavulanic acid. But, all MRCNS isolates were found to be susceptible to vancomycin. All *S. hominis*, *S. warneri* and *S. haemolyticus* isolates displayed multiple antimicrobial resistance (Table 1).

Prevalence of Resistance Genes

The *mecA* was detected in all strains. Of the 14 erythromycin-resistant (ER) isolates, 12 (85.7%) were positive for *ermC*, followed by *ermB* (9/14; 64.3%), *mphC* (9/14; 64.3%),

msrA (7/14; 50.0%) and *ermA* (1/14, 7.1%). The *tetK* was the most prevalent gene among tetracycline resistant isolates, detected alone in 8 (61.5%) isolates, in combination with *tetM* in 3 (42.8%) isolates. The *tetM* was detected in two (15.4%) isolates. Among aminoglycoside-resistant isolates, *aac(6')/aph(2'')* was detected in three (60%) strains, *aph(3')-IIIa* and *ant(4')-Ia* in one strain, and *ant(4')-Ia* in one isolate. Eight clindamycin resistant isolates were positive for *InuA* gene. While only three isolates carried *ileS-2* gene among five mupirocin resistant isolates, *fusB* and *fusC* genes were not detected in one fusidic acid resistant isolate (Table 1).

Table 1. Antimicrobial resistance phenotypes, genotypes and SCCmec types of methicillin resistant coagulase negative staphylococci isolated from dogs
Tablo 1. Köpeklerden izole edilen metisilin dirençli koagülaz negatif stafilokokların antimikrobiyal direnç fenotipleri, genotipleri ve SCCmec tipleri

MRCoNS Species	Phenotype*	Genotype	SCCmecType
<i>S. epidermidis</i>	OXA, E	<i>mecA, ermB, ermC, mphC</i>	I
<i>S. epidermidis</i>	OXA, E, MUP, CIP	<i>mecA, ermB</i>	IV
<i>S. epidermidis</i>	OXA, TE, MUP	<i>mecA, tetK, ileS-2R</i>	IV
<i>S. epidermidis</i>	OXA	<i>mecA</i>	III
<i>S. epidermidis</i>	OXA, TE, E, DA, CIP	<i>mecA, tetK, ermC, msrA, mphC, lnuA</i>	II
<i>S. epidermidis</i>	OXA, SXT	<i>mecA</i>	IV
<i>S. epidermidis</i>	OXA, TE, E, SXT	<i>mecA, tetK, ermC, msrA, mphC</i>	IV
<i>S. epidermidis</i>	OXA, E, MUP	<i>mecA, ermB, ermC, msrA, ileS-2R</i>	III
<i>S. epidermidis</i>	OXA, TE, E, DA, FD	<i>mecA, tetK, ermB, ermC, mphC</i>	II
<i>S. epidermidis</i>	OXA, E, CN, DA, QD, MUP	<i>mecA, ermB, ermC, msrA, mphC, aac(6')/aph(2''), lnuA, ileS-2R</i>	II
<i>S. epidermidis</i>	OXA	<i>mecA</i>	III
<i>S. epidermidis</i>	OXA, TE, E, DA, CIP	<i>mecA, tetK, ermC, msrA, mphC, lnuA</i>	II
<i>S. lentus</i>	OXA, TE	<i>mecA, tetK, tetM</i>	II
<i>S. lentus</i>	OXA, TE, CN, RD	<i>mecA, tetM, aac(6')/aph(2'')</i>	II
<i>S. lentus</i>	OXA, TE, DA	<i>mecA, tetK, tetM, lnuA</i>	II
<i>S. lentus</i>	OXA, TE, E, DA, SXT, CIP	<i>mecA, tetK, tetM, lnuA, ermA, ermB, ermC, mphC</i>	III
<i>S. lentus</i>	OXA, AMC, SXT, CIP	<i>mecA</i>	II
<i>S. lentus</i>	OXA, TE	<i>mecA, tetK</i>	IV
<i>S. hominis</i>	OXA, TE, CN, RD	<i>mecA, tetK, aac(6')/aph(2'')</i>	II
<i>S. hominis</i>	OXA, TE, E, CN, DA	<i>mecA, tetM, lnuA, ermB, ermC, msrA, mphC, aph(3')-IIIa, ant(4')-Ia</i>	III
<i>S. hominis</i>	OXA, E, MUP	<i>mecA, ermC</i>	III
<i>S. hominis</i>	OXA, TE, E, SXT	<i>mecA, tetK, ermB, mphC</i>	III
<i>S. warneri</i>	OXA, E, DA, CN	<i>mecA, lnuA, ermB, ermC, msrA, ant(4')-Ia</i>	III
<i>S. arlettae</i>	OXA, SXT	<i>mecA</i>	II
<i>S. haemolyticus</i>	OXA, E, RD, CIP	<i>mecA, ermC</i>	III

* OXA: oxacillin, E: erythromycin, SXT: trimethoprim-sulfamethoxazole, QD: quinopristin-dalfopristin, CN: gentamicin, CIP: ciprofloxacin; MUP: mupirocin, FD: fusidic acid, RA: rifampicin, AMC: amoxicillin-clavulanic acid, DA: clindamycin, TE: tetracycline

The most prevalent SCCmec type were SCCmec II (40%), followed by SCCmec III (36%), SCCmec V (20%), and SCCmec I (4%) (Fig. 2, 3).

DISCUSSION

Considering the high zoonotic potential of MRSA and MRSP, it is encouraging that MRSA and MRSP were not isolated from any dogs sampled in this study. This indicates that these agents have a very low in the total population of dogs admitted to clinics. Similar results have been reported in Turkey and Denmark ^{4,6}.

CNS are recognised as a major cause of nosocomial infections, especially in immunocompromised patients ². An increase of MRCNS strains was reported from 38% in 1996 to 67.5% in 2007 in Turkey ²³. Although, importance of CNS in veterinary medicine or potential for zoonotic infection is not well known. In recent years, CNS has steadily gained importance as veterinary pathogens and implicated in

mastitis, pyoderma, cystitis, arthritis and respiratory system infections in various animal species ^{8,9,24,25}.

The most prevalent SCCmec types were II (40%, 10/25) and III (36%, 9/25), identified among all MRCNS. Type IV is predominant among *S. epidermidis* isolates. SCCmec type IV was more frequently acquired by *S. epidermidis*, which is in accordance with the enhanced mobility of this type of SCCmec. A majority of hospital-acquired MRSA (HA-MRSA) isolates harbor SCCmec type I-III ²⁶, SCCmec type III were found to be more prevalent among human MRSA strains with a prevalence rate of 82.1% in Turkey ²⁷. Dominance of HA-MRSA SCCmec type II and III indicate that dogs are a large reservoir of SCCmec in MRCNS. It is reasonable to assume that CoNS of dog origin share a common pool of SCCmec with MRSA and thus pose a potential threat to public and animal health.

Among 25 MRCNS isolated, *S. epidermidis*, *S. lentus* and *S. hominis* were most prevalent species. To the best of our knowledge, this is the first report of *mecA*-mediated

methicillin resistance in *S. arlettae* in dogs. *S. arlettae* is one of the CoNS isolated from the skin of mammals and poultry²⁸. Bağcigil et al.⁴ reported *S. epidermidis* (n=7) and *S. haemolyticus* (n=3) as more prevalent species in dogs in Denmark. Another study carried out in Turkey, *S. hominis* was found to be the more prevalent among MRCNS in dogs⁶. Although no information is available on the frequency of nosocomial pathogens in veterinary hospitals, some species, mainly *S. epidermidis*, *S. haemolyticus*, *S. hominis* have been isolated from nosocomial infections in Turkey^{23,29}.

Methicillin resistant strains have high rates of resistance to other classes of antimicrobials than methicillin susceptible strains². In this study, MRCNS strains were resistant to clinically relevant antimicrobial drugs such as mupirocin, fusidic acid, quinopristin-dalfopristin, rifampicin in various levels. These findings confirm that MRS may pose a major therapeutic challenge for veterinarians due to limited choice of antimicrobials. Taken into consideration of multiple resistance, antimicrobial selective pressure is likely to play a key role in the emergence and spread of MRCNS among dog population.

All except two MRCNS isolates carried more than one antimicrobial resistance gene. In particular, one *S. hominis* isolate carried nine resistance genes that confer resistance to five antimicrobials. Hanssen and Sollid³⁰ reported that resistant strains of CNS might serve as pool of antimicrobial resistance genes. Because majority of resistance determinants carried by mobile genetic elements, and this favors transfer of resistance genes within and across bacterial species and even across genus borders

In conclusion, the results indicate that MRCNS are common in dogs in Turkey. Therefore, the resistance trends observed among staphylococci isolated from the nasal cavity of dogs seem to reflect the national and local patterns of antimicrobial usage in this animal species. However, further studies based on larger and more representative study populations are needed to determine the true prevalence of these agents.

REFERENCES

- Weese JS, Van Duijkeren E:** Methicillin-resistant *Staphylococcus aureus* and *Staphylococcus pseudintermedius* in veterinary medicine. *Vet Microbiol*, 140, 418-429, 2010.
- Piette A, Verschraegen G:** Role of coagulase-negative staphylococci in human disease. *Vet Microbiol*, 134, 45-54, 2009.
- Pyörälä S, Taponen S:** Coagulase-negative staphylococci-emerging mastitis pathogens. *Vet Microbiol*, 134, 3-8, 2009.
- Bağcigil FA, Moodley A, Baptiste KE, Jensen VF, Guardabassi L:** Occurrence, species distribution, antimicrobial resistance and clonality of methicillin- and erythromycin-resistant staphylococci in the nasal cavity of domestic animals. *Vet Microbiol*, 121, 307-315, 2007.
- Vengust M, Anderson ME, Rousseau J, Weese JS:** Methicillin-resistant staphylococcal colonization in clinically normal dogs and horses in the community. *Lett Appl Microbiol*, 43, 602-606, 2006.
- Bağcigil AF, İkiz S, Güzel Ö, Parkan Ç, Ilgaz A:** Kliniğe getirilen köpeklerden ve klinik ortamından metisiline dirençli stafilkokların izolasyonu ve *mecA* geninin PCR ile araştırılması. VII. Ulusal Veteriner Mikrobiyoloji Kongresi (Uluslararası Katılımlı), 26-28 Eylül 2006, Side-Antalya, 2006.
- Oliveira DC, de Lencastre H:** Multiplex PCR strategy for rapid identification of structural types and variants of the *mec* element in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Chemother*, 46, 2155-61, 2002.
- Kaynarca S, Türkyılmaz S:** Methicillin resistance and slime positivity of staphylococci isolated from bovine mastitis. *Kafkas Univ Vet Fak Derg*, 16 (4): 567-572, 2010.
- İnegöl E, Türkyılmaz S:** Determination of SCC*mec* types in methicilline resistant staphylococci isolated from cows and farm workers. *Ankara Üniv Vet Fak Derg*, 59, 89-93, 2012.
- Suau A, Bonnet R, Sutren M, Godon JJ, Gibson G, Collins MD, Dore J:** Direct rDNA community analysis reveals a myriad of novel bacterial lineages within the human gut. *Appl Environ Microbiol*, 65, 4799-4807, 1999.
- Sghir A, Antonopoulos D, Mackie RI:** Design and evaluation of a lactobacillus group-specific ribosomal RNA-targeted hybridization probe and its application to the study of intestinal microecology in pigs. *Syst Appl Microbiol*, 21, 291-296, 1998.
- Clinical and Laboratory Standards Institute:** Performance standards for Disc and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard-third Edition (M31-A3), CLSI, Wayne, PA, 2008
- Toma E, Barriault D:** Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for Gram-positive cocci. *J Clin Microbiol*, 33, 1712-1715, 1995.
- Fuchs PC, Jones RN, Barry AL:** Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic. *J Clin Microbiol*, 28, 608-609, 1990.
- Mclaws F, Chopra I, O'Neill AJ:** High prevalence of resistance to fusidic acid in clinical isolates of *Staphylococcus epidermidis*. *J Antimicrob Chemother*, 61, 1040-1043, 2008.
- Choi SM, Kim SH, Kim HJ, Lee DG, Choi JH, Yoo JH, Kang JH, Shin WS, Kang MW:** Multiplex PCR for the detection of genes encoding aminoglycoside modifying enzymes and methicillin resistance among *Staphylococcus* species, 18, 631-636, 2003.
- Strommenger B, Kettlitz C, Werner G, Witte W:** Multiplex PCR assay for simultaneous detection of nine clinically relevant antibiotic resistance genes in *Staphylococcus aureus*. *J Clin Microbiol*, 41, 4089-4094, 2003.
- Lüthje P, Schwarz S:** Antimicrobial resistance of coagulase-negative staphylococci from bovine subclinical mastitis with particular reference to macrolide-lincosamide resistance phenotypes and genotypes. *J Antimicrob Chemother*, 57, 966-969, 2006.
- Martineau F, Picard FJ, Lansac N, Ménard C, Roy PH, Ouellette M, Bergeron MG:** Correlation between the resistance genotype determined by multiplex PCR assays and the antibiotic susceptibility patterns of *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Antimicrob Agents Chemother*, 44, 231-238, 2000.
- Jensen LB, Frimodt-Møller N, Aarestrup FM:** Presence of *erm* gene classes in gram-positive bacteria of animal and human origin in Denmark. *FEMS Microbiol Lett*, 170, 151-158, 1999.
- Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J:** Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. *Antimicrob Agents Chemother*, 43, 1062-1066, 1999.
- Nunes EL, dos Santos KR, Mondino PJ, Bastos Mdo C, Giambiagi-de Marval M:** Detection of *ileS-2* gene encoding mupirocin resistance in methicillin-resistant *Staphylococcus aureus* by multiplex PCR. *Diagn Microbiol Infect Dis*, 34, 77-81, 1999.
- Köksal F, Yasar H, Samasti M:** Antibiotic resistance patterns of coagulase-negative staphylococcus strains isolated from blood cultures of septicemic patients in Turkey. *Microbiol Res*, 164, 404-410, 2009.
- Taponen S, Pyörälä S:** Coagulase-negative staphylococci as cause of bovinemastitis-Not so different from *Staphylococcus aureus*? *Vet Microbiol*, 134, 29-36, 2009.
- van Duijkeren E, Box AT, Heck ME, Wannet WJ, Fluit AC:** Methicillin-

resistant staphylococci isolated from animals. *Vet Microbiol*, 103, 91-97, 2004.

26. Martins A, Cunha de ML: Methicillin resistance in *Staphylococcus aureus* and coagulase negative staphylococci: epidemiological and molecular aspects. *Microbiol Immunol*, 51, 787-795, 2007.

27. Kılıç A, Güçlü AÜ, Şenses Z, Bedir B, Aydoğan H, Başustaoğlu AC: Staphylococcal cassette chromosome *mec* (SCC*mec*) characterization and panton-valentine leukocidin gene occurrence for methicillin-resistant *Staphylococcus aureus* in Turkey, from 2003 to 2006. *Antonie van Leeuwenhoek*, 94, 607-614, 2008.

28. Schleifer KH, Kilpper-Balz R, Devriese LA: *Staphylococcus arlettae* sp. nov., *S. equorum* sp. nov. and *S. kloosii* sp. nov.: Three new coagulase-negative, novobiocin-resistant species from animals. *Syst Appl Microbiol*, 5, 501-509, 1984.

29. Biçer AT: Hastane izolatu *Staphylococcus aureus* ve koagülaz negatif staphylococcus suşlarında metisilin direncinin farklı yöntemlerle araştırılması. *Uzmanlık Tezi*. Çukurova Üniversitesi Tıp Fakültesi Mikrobiyoloji Anabilim Dalı, Adana, 2009.

30. Hanssen AM, Ericson Sollid JU: SCC*mec* in staphylococci: genes on the move. *FEMS Immunol Med Microbiol*, 46, 8-20, 2006.